跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
ATRIPLA - Health Canada Drug Approval Details
Approvals
/
Health Canada
/
ATRIPLA
Authorized
STANDARD
ATRIPLA
Gilead Sciences, LLC
🇨🇦 Health Canada
Approval Date
Jul 4, 2025
Approval ID
687b58c49bde7a73
Company
Gilead Sciences, LLC
Type
Standard
Approval Details
Approval Id
687b58c49bde7a73
Drug Approval Canada Name
ATRIPLA
Product Name
ATRIPLA
Status
Cancelled Post Market
Status Date
2021-12-22
Original Market Date
2007-10-23
Din
02300699
Drug Class
Human
Dosage Form
Tablet
Route Of Administration
Oral
Schedule
Prescription
Ahfs
08:18.08.20
Atc Original
J05AR06 EMTRICITABINE, TENOFOVIR DISOPROXIL AND EFAVIRENZ
Atc Name
j 05 ar 06
Aig Number
0352327001
Company Name
Gilead Sciences, LLC
Company Address
333 Lakeside Drive, Foster City, California, United States, 94404
Company Detail Path
/organization/gilead-sciences-llc
Company Information
Pharmaceutical Company Name
Gilead Sciences, LLC
Country Name
United States
Province Name
California
City Name
foster city,california,country_us
Address
333 Lakeside Dr
Active Ingredients
EFAVIRENZ
600 MG
EMTRICITABINE
200 MG
TENOFOVIR DISOPROXIL FUMARATE
300 MG
Authorized
Quick Info
Agency
Health Canada
Country
🇨🇦
Approval Date
Jul 4, 2025
Approval ID
687b58c49bde7a73
Type
Standard
Back to Health Canada Approvals